gaining significant traction of various market players of implantable cardiac pacemakers with
affordable costs, which in turn are expected to drive growth of implantable cardiac pacemakers
market. For instance, in February 2017, Abbott received the Food and Drug Administration (FDA)
approval for its MR-conditional labeling for both of its products i.e. Assurity MRI pacemaker and
the Tendril MRI pacing lead. Furthermore, introduction of advance technology such as wireless and
automated pacemaker monitoring pacemakers are gaining significant traction among healthcare
providers.
For instance, in 2016, Biotronik launched CardioMessenger Smart, portable monitoring device in
the U.S. This system is about the size of a modern smartphone used to keep pacemaker, Implantable
Cardioverter Defibrillator (ICD) and Insertable Cardiac Monitor (ICM) patients connected to their
physician remotely. This CardioMessenger Smart helps to ensure patient compliance and the
consistent transmission of data necessary for physicians to identify and prevent potential cardiac
events. Thus, such wireless technologies are gaining traction of vendors, which is expected to drive
the growth of the implantable cardiac pacemaker market
Increasing Prevalence of Cardiovascular Disease is Expected to Drive Growth of Implantable
Cardiac Pacemaker Market
Increasing incidence of cardiovascular diseases is expected to boost growth of the implantable
cardiac pacemakers market over the forecast period. According to the Centers for Disease Control
and Prevention (CDC), August 2017 data findings, Atrial Fibrillation (AFib or AF) is most common
type of heart arrhythmia, which affected an estimated 2.7 to 6.1 million people in the U.S. and the
number is expected to increase in near future. Furthermore, Atrial Fibrillation cases increase with
age and it is more prominent in men than women. Moreover, increasing number of geriatric
population across the various regions worldwide along with high prevalence of heart disease is
expected to propel demand for implantable cardiac pacemakers in the near future.
However, implantable pacemakers associated infections in cardiac patients is hindering growth of
the implantable cardiac pacemaker market. Pacemaker surgery is associated with swelling, bruising,
bleeding, or infection of the area where the pacemaker was placed leading to blood vessel or nerve
damage and adverse reaction of medicine used during the pacemaker implantation surgery, which
may reduce the adoption of implantable cardiac implants in patients.
For More Information @
https://www.coherentmarketinsights.com/market-insight/implantable-cardiac-pacemaker-
market-1663
Global Key Players:
Some of the key players operating in implantable cardiac pacemaker market include Medtronic plc,
BIOTRONIK, Inc., Boston Scientific Corporation, St. Jude Medical, Vitatron Holding B.V., Shree
Pacetronix Ltd., MEDICO S.p.A., Lepu Medical Technology Co Ltd., LivaNova PLC, and Qinming
Medical.
Detailed Segmentation:
•Global Implantable Cardiac Pacemaker Market, By Product Type:
•Single Chamber Pacemaker
•Dual Chamber Pacemaker
•Biventricular Pacemaker
•Global Implantable Cardiac Pacemaker Market, By Application: